XML 58 R44.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Intangible Assets and Royalty Agreement Intangible Asssets Activity Summary (Details) - USD ($) |  | 12 Months Ended |
--- | --- | --- | ---
Jan. 29, 2007 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Intangible assets, gross carrying value |  |  | $ 15,627,000 | $ 14,776,000 |  |
Less Accumulated amortization |  |  | (4,864,000) | (3,931,000) |  |
Intangible Assets, Net |  |  | 10,763,000 | 10,845,000 |  |
Net book value |  |  | 9,755,000 |  |  |
Amortization of intangible assets |  |  | 933,000 | 928,000 | $ 1,054,000 |
Tradenames & Trademarks |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross carrying value, indefinite lived |  |  | 1,008,000 | 1,008,000 |  |
Tradenames & Trademarks | Surgical Biologics, LLC |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross carrying value, indefinite lived |  |  |  |  |  | $ 1,008,000
In Process Research & Development |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross carrying value, indefinite lived |  |  | 25,000 | 25,000 |  |
In Process Research & Development | Surgical Biologics, LLC |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross carrying value, indefinite lived |  |  |  |  |  | 25,000
Patents in Process |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross carrying value, indefinite lived |  |  | $ 1,823,000 | 1,082,000 |  |
Licenses |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Weighted Average Amortization Lives | [1],[2],[3] |  | 10 years |  |  |
Gross carrying value | [1],[2],[3] |  | $ 1,009,000 | 1,009,000 |  |
Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Acquisition price |  | $ 996,000 |  |  |  |
Maximum time of approval |  | 30 days |  |  |  |
Contingent payments to licensor |  |  | $ 200,000 |  |  |
Contingent royalty to be paid to licensor |  |  | 3.00% |  |  |
Annual royalty payment |  | $ 50,000 |  |  |  |
Net book value |  |  | $ 110,000 |  |  |
Licenses | Surgical Biologics, LLC |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross carrying value | [1],[2],[3] |  |  |  |  | 13,000
Patents & Know How |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Weighted Average Amortization Lives |  |  | 17 years |  |  |
Gross carrying value |  |  | $ 8,001,000 | 7,891,000 |  |
Patents & Know How | Surgical Biologics, LLC |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross carrying value |  |  |  |  |  | 7,690,000
Finite-lived intangible assets, costs |  |  | $ 110,000 |  |  |
Customer & Supplier Relationships |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Weighted Average Amortization Lives |  |  | 14 years |  |  |
Gross carrying value |  |  | $ 3,761,000 | $ 3,761,000 |  |
Customer & Supplier Relationships | Surgical Biologics, LLC |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |
Gross carrying value |  |  |  |  |  | $ 3,761,000
[1] | Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
[2] | On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000.
[3] | On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.

X
- Definition Royalty payment percentage on all commercial sales revenue from the licensed products. + References No definition available. + Details
Name: | mdxg_ContingentRoyaltyToBePaidToLicensor
Namespace Prefix: | mdxg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total of accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance. + References No definition available. + Details
Name: | mdxg_IntangibleAssetsAccumulatedAmortization
Namespace Prefix: | mdxg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum amount of time the entity has to obtain approval by the FDA to allow the sale of the product. + References No definition available. + Details
Name: | mdxg_PeriodOfApprovalMaximum
Namespace Prefix: | mdxg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from a business combination. + References No definition available. + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount before accumulated amortization of intangible assets, excluding goodwill. + References No definition available. + Details
Name: | us-gaap_IntangibleAssetsGrossExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mdxg_SurgicalBiologicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mdxg_PatentsinProcessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mdxg_ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |